Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDSUlrich Keilholz, Carmen Scheibenbogen, Wolf-Karsten Hofmann et al.|Blood|2009Cited by 300
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent YearsAli Bazarbachi, Mohamad Mohty, Christoph Schmid et al.|Clinical Cancer Research|2020Cited by 81